Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**C-117** is an investigational multi-ingredient traditional Chinese medicine formula developed by Guangzhou University of Traditional Chinese Medicine. It is described in clinical-trial materials as a formula containing two herbal and two insect-derived medicinal components, intended under traditional Chinese medicine principles to promote blood circulation and resolve blood stasis. C-117 has been evaluated in randomized, double-blind, placebo-controlled Phase 2 studies for prevention of restenosis after intracranial artery stenting and for vulnerable carotid atherosclerotic plaques. Its individual active constituents, molecular targets, pharmacokinetics, and validated molecular mechanism have not been publicly specified. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT03008798/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on C-117 (Guangzhou University of Chinese Medicine).